biostudies-literatureRoesch RMRoche Pharma AG, Grenzach-Wyhlen, Germanye096617https://www.ebi.ac.uk/biostudies/studies/S-EPMC11956294biostudies-literatureUnknown15(3)<h4>Background</h4>Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade of the T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT)-receptor may synergistically foster the immune-related response. Several trials are currently investigating the combination of neoadjuvant platinum-based chemotherapy and dual checkpoint inhibition prior to curative surgery. The investigator-initiated NeoTRACK trial (EU CT number: 2022-501322-38-00; ClinicalTrials.gov identifier: NCT05825625; IKF056) aims to evaluate the feasibility and safety of perioperative anti-PD-L1 (by atezoBMJ openNeoTRACK trial: &lt;u&gt;Neo&lt;/u&gt;adjuvant &lt;u&gt;T&lt;/u&gt;i&lt;u&gt;R&lt;/u&gt;agolumab, &lt;u&gt;A&lt;/u&gt;tezolizumab and &lt;u&gt;C&lt;/u&gt;hemotherapy - dissection of IO- efficacy in NSCLC by longitudinal trac&lt;u&gt;K&lt;/u&gt;ing - protocol of a non-randomised, open-label, single-arm, phase II study.PMC11956294Financial support and supply of medical drugsHegedus BCvetkovic JRoesch RMStenzinger ASchneider MWiesweg MKlotz LVChristopoulos PBolukbas SEichhorn FThomas MEichhorn MEKirchner MBozorgmehr FSchramm ADoerr FWinter HSchnorbach JGriffo RSchuler MAllgaeuer MfalseNeoTRACK trial: &lt;u&gt;Neo&lt;/u&gt;adjuvant &lt;u&gt;T&lt;/u&gt;i&lt;u&gt;R&lt;/u&gt;agolumab, &lt;u&gt;A&lt;/u&gt;tezolizumab and &lt;u&gt;C&lt;/u&gt;hemotherapy - dissection of IO- efficacy in NSCLC by longitudinal trac&lt;u&gt;K&lt;/u&gt;ing - protocol of a non-randomised, open-label, single-arm, phase II study.<h4>Background</h4>Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade of the T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT)-receptor may synergistically foster the immune-related response. Several trials are currently investigating the combination of neoadjuvant platinum-based chemotherapy and dual checkpoint inhibition prior to curative surgery. The investigator-initiated NeoTRACK trial (EU CT number: 2022-501322-38-00; ClinicalTrials.gov identifier: NCT05825625; IKF056) aims to evaluate the feasibility and safety of perioperative anti-PD-L1 (by atezo2025-01-01T00:00:00Z2025 Mar2026-06-01T19:09:53.099Z2026-05-19T03:07:08.644ZS-EPMC119562944014798510.1136/bmjopen-2024-096617